MedTrace Logo

Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fasting Condition

NCT01513720 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-01-20

No results posted yet for this study

Summary

This is an single dose,two-way, crossover, oral bioequivalence study.

Conditions

  • Healthy

Interventions

DRUG

Lamotrigine

Lamotrigine Tablets 200 mg

DRUG

Lamictal®

Lamictal® 200 mg Tablets

Sponsors & Collaborators

  • Dr. Reddy's Laboratories Limited

    lead INDUSTRY

Principal Investigators

  • Dr. Ralph Scallion, MD · AAI Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
44 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2002-12-31
Completion
2002-12-31

Countries

  • United States

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01513720 on ClinicalTrials.gov